We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Multiple Sclerosis Study Could Push Cannabis Compounds Closer to FDA Approval

Jun 11, 2018 | Original story from MMJ International Holdings

Multiple Sclerosis Study Could Push Cannabis Compounds Closer to FDA Approval

MMJ International Holding's has announced the filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's THC/CBD pharmaceutical compounds for treating and/or preventing symptoms associated with multiple sclerosis (MS).


Dr. Bianca Weinstock-Guttman is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium will execute the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients. MMJ BioScience's will be providing new evidence regarding clinical outcomes leading to commercial success in the scientific process of MMJ BioScience's first pharmaceutical (THC) cannabidiol (CBD) derived medicine.


MMJ's first clinical trial of cannabis-based medicines involving patients suffering from Multiple Sclerosis and its related forms of severe pain and spasticity will be seeking FDA permission to proceed to undertake a pharmaceutical research study to develop a prescription cannabis-based medicine. MMJ will soon commence their Phase 2 clinical trials with the guidance of their clinical research organization.


Timothy Moynahan Chairman of MMJ stated, ""Our goal is to conduct clinical research and generate safety and efficacy data on our medication to support a comprehensive review by the FDA and approval as a prescription medicine that will deliver consistency and quality for Multiple Sclerosis patients." 


Moynahan further stated "That despite the growing acceptance of cannabis at the state level around the country, it really has no bearing on our strategy. The FDA will assess our new drug application (NDA) based only on our scientific data, irrespective of the drug being sourced from natural botanical materials."


This article has been republished from materials provided by MMJ International Holdings. Note: material may have been edited for length and content. For further information, please contact the cited source.